Skip to main content
BIAF logo

BIAF · bioAffinity Technologies, Inc. · Investor Relations

Track BIAF — free
$1.76 -0.09 (-4.86%)
Market Cap
$3.37M
Shares
1.82M
Volume · Nov 20 16.77K Avg daily vol (63 sessions) 3.6M

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Recent news

Date Headline
2026-11-17 bioAffinity Technologies Reports Record Monthly Testing Volume in October for Its Noninvasive CyPath® Lung Test
2026-11-11 bioAffinity Technologies Reports Record Monthly Testing Volume in October for Its Noninvasive CyPath® Lung Test
2026-11-06 bioAffinity Technologies Reports Third Quarter 2026 Results and Continued Momentum in CyPath ® Lung Commercialization CyPath ® Lung test unit sales double year to date over 2025, with solid gains in physician utilization and recurring orders; testing revenue increases 79% year-to-date
2026-11-06 bioAffinity Technologies Reports Third Quarter 2026 Results and Continued Momentum in CyPath® Lung Commercialization
2026-10-29 bioAffinity Technologies Highlights Importance of Link Between Early Lung Cancer Detection and Curative Treatment During National Lung Cancer Awareness Month
2026-10-15 bioAffinity Technologies to Present New Perspectives on CyPath® Lung’s Use for Cancer Risk Assessment at CHEST 2026
2026-10-13 bioAffinity Technologies to Present Positive Research Data in Development of Its New Test Measuring Asthma and COPD-Related Lung Inflammation and Drug-Related Receptors at CHEST 2026
2026-10-09 bioAffinity Technologies, Inc. Announces Closing of $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
2026-10-09 bioAffinity Technologies, Inc. Announces Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
2026-10-08 bioAffinity Technologies Announces Notification of Japanese Patent Allowance Covering Noninvasive CyPath® Lung and AI-Built Algorithm
2026-10-06 bioAffinity Technologies Reports Over 100% Growth in CyPath® Lung Sales Through Third Quarter 2026
2026-09-30 bioAffinity Technologies Promotes Veteran Awareness and Access to Its Noninvasive CyPath® Lung Cancer Test Through Distribution Partnership with Veteran-Owned AvMEDICAL
2026-09-22 bioAffinity Technologies to Present Positive Clinical and Veteran-Focused Data on CyPath® Lung at NAVREF 2026 Annual Conference
2026-09-17 bioAffinity Technologies Announces Grant of Hong Kong Patent for Company’s CyPath ® Lung Noninvasive Lung Cancer Diagnostic Dual patent protection in Hong Kong and China strengthens CyPath Lung’s positioning to enter Asian market Asia accounts for nearly two-thirds of lung cancer cases worldwide
2026-09-09 bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements BIAF continues to be listed and traded on Nasdaq
2026-09-03 bioAffinity Technologies to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-01 bioAffinity Technologies Advances CyPath ® Lung for Surveillance of Lung Cancer Survivors More than 680,000 Americans living with a history of lung cancer represent a significant population requiring ongoing surveillance
2026-08-20 bioAffinity Technologies Announces 1-for-15 Reverse Stock Split Effective at the Open of Trading on August 24, 2026
2026-08-18 bioAffinity Technologies and AvMEDICAL Announce Nationwide Federal Healthcare Distribution Agreement for CyPath® Lung
2026-08-14 bioAffinity Technologies Announces Pricing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules
2026-08-07 bioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath® Lung
2026-07-27 bioAffinity Technologies Publishes New Clinical Framework Addressing Growing Market for Pulmonary Nodule Risk Stratification and Early Lung Cancer Detection Using CyPath ® Lung
2026-07-22 bioAffinity Technologies and Pictor ® , Inc. Partner to Develop and Commercialize bioAffinity’s Diagnostics for Asthma and COPD
2026-07-07 bioAffinity Technologies’ Quarterly CyPath ® Lung Sales Double to New Record as Commercial Momentum Continues CyPath ® Lung sales volume for Q2 2026 grows more than 200% year-over-year and 30% over record-breaking prior quarter
2026-06-18 bioAffinity Technologies Announces Closing of $3.2 Million Offering

Past events

Date Event Type
2026-10-20 CHEST 2026 Conference
2026-09-16 H.C. Wainwright 28th Annual Global Investment Conference Conference
2026-07-21 Advancing Veteran Lung Health Webinar Event

Source: https://ir.bioaffinitytech.com/

Key facts CIK 1712762 CUSIP 09076W406 13F (30d) 21 filings 14 filers Visit website Investor relations